- Home
- REKR vs EDIT Comparison
REKR vs EDIT Comparison
Compare REKR & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REKR
- EDIT
- Stock Information
- Founded
- REKR 2017
- EDIT 2013
- Country
- REKR United States
- EDIT United States
- Employees
- REKR N/A
- EDIT N/A
- Industry
- REKR Telecommunications Equipment
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- REKR Telecommunications
- EDIT Health Care
- Exchange
- REKR Nasdaq
- EDIT Nasdaq
- Market Cap
- REKR 115.1M
- EDIT 108.1M
- IPO Year
- REKR N/A
- EDIT 2016
- Fundamental
- Price
- REKR $0.87
- EDIT $1.17
- Analyst Decision
- REKR
- EDIT Buy
- Analyst Count
- REKR 0
- EDIT 14
- Target Price
- REKR N/A
- EDIT $8.08
- AVG Volume (30 Days)
- REKR 3.7M
- EDIT 2.4M
- Earning Date
- REKR 03-31-2025
- EDIT 03-05-2025
- Dividend Yield
- REKR N/A
- EDIT N/A
- EPS Growth
- REKR N/A
- EDIT N/A
- EPS
- REKR N/A
- EDIT N/A
- Revenue
- REKR $43,817,000.00
- EDIT $32,314,000.00
- Revenue This Year
- REKR $33.40
- EDIT N/A
- Revenue Next Year
- REKR $41.09
- EDIT N/A
- P/E Ratio
- REKR N/A
- EDIT N/A
- Revenue Growth
- REKR 44.46
- EDIT N/A
- 52 Week Low
- REKR $0.78
- EDIT $1.12
- 52 Week High
- REKR $2.67
- EDIT $7.41
- Technical
- Relative Strength Index (RSI)
- REKR 34.15
- EDIT 38.94
- Support Level
- REKR $0.99
- EDIT $1.24
- Resistance Level
- REKR $1.18
- EDIT $1.32
- Average True Range (ATR)
- REKR 0.09
- EDIT 0.10
- MACD
- REKR 0.01
- EDIT -0.03
- Stochastic Oscillator
- REKR 13.98
- EDIT 1.22
About REKR Rekor Systems Inc.
Rekor Systems Inc is a United States-based company. The company is engaged in providing real-time roadway intelligence through AI-driven decisions. The firm uses artificial intelligence to analyze video streams and transform them into AI-driven decisions. The company's technology and machine learning models power all solutions, including Rekor Command for transportation management, Rekor Discover for urban mobility, and Rekor Scout for public safety, and commercial use. Its geographical segments are the United States and Others, of which the majority of its revenue comes from the United States.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.